<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Chemotherapeutic agents produce dose-limiting <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> through mechanisms that remain poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>We previously showed that AM1710, a cannabilactone CB₂ <z:chebi fb="4" ids="48705">agonist</z:chebi>, produces antinociception without producing central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>)-associated side effects </plain></SENT>
<SENT sid="2" pm="."><plain>The present study was conducted to examine the antinociceptive effect of AM1710 in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of neuropathic pain evoked by diverse chemotherapeutic agents (<z:chebi fb="2" ids="27899">cisplatin</z:chebi> and paclitaxel) </plain></SENT>
<SENT sid="3" pm="."><plain>A secondary objective was to investigate the potential contribution of alpha-chemokine receptor (CXCR4) signaling to both chemotherapy-induced <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and CB₂ <z:chebi fb="4" ids="48705">agonist</z:chebi> efficacy </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: AM1710 (0.1, 1 or 5 mg/kg i.p.) suppressed the maintenance of mechanical and cold <z:mp ids='MP_0003177'>allodynia</z:mp> in the <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and paclitaxel models </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-allodynic effects of AM1710 were blocked by the CB₂ <z:chebi fb="68" ids="48706">antagonist</z:chebi> AM630 (3 mg/kg i.p.), but not the CB1 <z:chebi fb="68" ids="48706">antagonist</z:chebi> AM251 (3 mg/kg i.p.), consistent with a CB₂-mediated effect </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, blockade of CXCR4 signaling with its receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> AMD3100 (10 mg/kg i.p.) failed to attenuate mechanical or cold hypersensitivity induced by either <z:chebi fb="2" ids="27899">cisplatin</z:chebi> or paclitaxel </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, blockade of CXCR4 signaling failed to alter the anti-allodynic effects of AM1710 in the paclitaxel model, further suggesting distinct mechanisms of action </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results indicate that activation of cannabinoid CB₂ receptors by AM1710 suppresses both mechanical and cold <z:mp ids='MP_0003177'>allodynia</z:mp> in two distinct models of chemotherapy-induced neuropathic pain </plain></SENT>
<SENT sid="9" pm="."><plain>By contrast, CXCR4 signaling does not contribute to the maintenance of chemotherapy-induced established <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> or efficacy of AM1710 </plain></SENT>
<SENT sid="10" pm="."><plain>Our studies suggest that CB₂ receptors represent a promising therapeutic target for the treatment of toxic <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathies</z:e> produced by <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and paclitaxel chemotherapeutic agents </plain></SENT>
</text></document>